This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ke, N. Articles by Li, Q.-X. Search for Related Content PubMed PubMed Citation Articles by Ke, N. Articles by Li, Q.-X.

Research Articles: Therapeutics, Targets, and Development

Orphan G protein–coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway

¹ Immusol, Inc., San Diego, California and ² Affymetrix, Inc., Santa Clara, California

Requests for reprints: Qi-Xiang Li, Immusol, Inc., 10790 Roselle Street, San Diego, CA 92121. Phone: 858-824-1100, ext. 101; Fax: 858-824-1112. E-mail: li{at}immusol.com

Abstract

GPR56 is an orphan G protein–coupled receptor, mutations of which have recently been associated with bilateral frontoparietal polymicrogyria, a rare neurologic disease that has implications in brain development. However, no phenotype beyond central nervous system has yet been described for the GPR56-null mutations despite abundant GPR56 expression in many non–central nervous system adult tissues. In the present study, we show that higher GPR56 expression is correlated with the cellular transformation phenotypes of several cancer tissues compared with their normal counterparts, implying a potential oncogenic function. RNA interference–mediated GPR56 silencing results in apoptosis induction and reduced anchorage-independent growth of cancer cells via increased anoikis, whereas cDNA overexpression resulted in increased foci formation in mouse fibroblast NIH3T3 cell line. When GPR56 silencing was induced in vivo in several xenograft tumor models, significant tumor responses (including regression) were observed, suggesting the potential of targeting GPR56 in the development of tumor therapies. The expression profiling of GPR56-silenced A2058 melanoma cell line revealed several genes whose expression was affected by GPR56 silencing, particularly those in the integrin-mediated signaling and cell adhesion pathways. The potential role of GPR56 in cancer cell adhesion was further confirmed by the observation that GPR56 silencing also reduced cell adhesion to the extracellular matrix, which is consistent with the observed increase in anoikis and reduction in anchorage-independent growth phenotypes. The oncogenic potential and apparent absence of physiologic defects in adult human tissues lacking GPR56, as well as the targetable nature of G protein–coupled receptor by small molecule or antibody, make GPR56 an attractive drug target for the development of cancer therapies. [Mol Cancer Ther 2007;6(6):1840–50]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

³ Supplementary data for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

⁴ http://www.ingenuity.com

Received 2/12/07; revised 4/ 9/07; accepted 5/ 2/07.

This article has been cited by other articles:

				T. Iguchi, K. Sakata, K. Yoshizaki, K. Tago, N. Mizuno, and H. Itoh Orphan G Protein-coupled Receptor GPR56 Regulates Neural Progenitor Cell Migration via a G{alpha}12/13 and Rho Pathway J. Biol. Chem., May 23, 2008; 283(21): 14469 - 14478. [Abstract] [Full Text] [PDF]